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A B S T R A C T
Heart failure is currently a social welfare and economic burden. In particular, the prevalence of heart
failure with preserved ejection fraction (HFpEF) has increased and is currently equal to that of heart
failure with reduced ejection fraction (HFrEF). Prognosis of HFrEF has improved in the past two decades,
because many clinical studies have revealed the effectiveness of several pharmacological and non-
pharmacological interventions for HFrEF patients, one of which is b-blockers. In contrast, there is no
established therapeutic intervention to provide beneﬁcial effects on HFpEF, and mortality and morbidity
of HFpEF are currently as poor as those of HFrEF. This review will discuss b-blockers from a standpoint of
therapeutic strategy for HFpEF.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Half of the patients with the clinical syndrome of heart failure
(HF) in the community as well as those hospitalized for acute
decompensated HF have preserved ejection fraction in the current
era [1,2]. The incidence of HF increases with age, and the* Correspondence to: Division of Cardiovascular Medicine, Endocrinology and
Metabolism, Department of Molecular Medicine and Therapeutics, Faculty of Medicine,
Tottori University, 86, Nishi-cho, Yonago 683-8503, Japan. Tel.: +81 859 38 6517;
fax: +81 859 38 6519.
E-mail address: ykazuhiro@med.tottori-u.ac.jp
http://dx.doi.org/10.1016/j.jjcc.2015.02.004
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsprevalence of HF is speculated to increase by 46% from 2012 to
2030 in the USA [3]. Patients with HF with preserved ejection
fraction (HFpEF) are older and more often female compared to
those with HF with reduced ejection fraction (HFrEF) [1], and such
clinical characteristics of HFpEF lead to the continuous increase in
its prevalence among HF patients [4].
The accumulated evidence about the effects of therapeutic
interventions on HFrEF has resulted in the improvement of its
prognosis, although not satisfactorily [5]. In contrast, there has
been no established therapeutic strategy to be efﬁcacious against
HFpEF. Its prognosis has not changed over the past decades [5] and
is currently as poor as that of HFrEF [5–7]. Therefore, it is an exigent
issue to ﬁnd out effective therapeutic intervention for HFpEF. reserved.
Fig. 1. Kaplan–Meier survival curves of the heart failure with preserved ejection
fraction model rats of an untreated group, a group treated with low dose of
bisoprolol (12.5 mg/kg/day) and a group treated with high dose of bisoprolol
(250 mg/kg/day). The survival rate was improved by the administration of
bisoprolol, and the effects of bisoprolol were dose-dependent.
Reproduced with permission from Nishio et al. [21].
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system in HFpEF
Previous clinical trials have demonstrated the beneﬁcial effects
of the inhibition of renin–angiotensin–aldosterone system (RAAS)
in HFrEF, and its principal mechanism is to prevent structural
remodeling such as myocardial hypertrophy and ﬁbrosis. Myocar-
dial hypertrophy and ﬁbrosis are also observed in HFpEF patients
[8,9] and are considered to play crucial roles in the development of
signs and symptoms of HF. Our experimental studies have shown
that the inhibition of RAAS provides beneﬁcial effects on HFpEF
model rats [10–13]. However, clinical trials to assess the effects of
pharmacological RAAS inhibition on clinical outcomes of HFpEF
(Table 1) have failed to reveal its beneﬁts [14–17]. The discrepancy
between experimental and clinical studies may be partly explained
as follows. First, the experimental studies have assessed only the
preventive effects of interventions, not therapeutic effects, because
the administration of drugs was initiated after the development of
left ventricular (LV) diastolic dysfunction but before the onset of
HF. This may be supported by the subanalysis of I-Preserve trial
that showed the beneﬁcial effects of irbesartan in HFpEF patients
with low, but not high, values of baseline plasma amino-terminal
pro-brain natriuretic peptide [18]. Second, pathophysiology of
HFpEF is heterogeneous, and the animal model only represents a
part of HFpEF.
The effects of b-blockers in HFpEF
It is well known that b-blockers signiﬁcantly reduce mortality
and morbidity of HFrEF patients, although the mechanisms of the
beneﬁts are not well clariﬁed. Our clinical study showed that
b-blockers improved LV diastolic function and symptoms of HFrEF
patients even without changes in LV systolic function [19]. There-
fore, its beneﬁcial effects on HFpEF have been expected, and our’s
and other experimental studies demonstrated that the adminis-
tration of b-blockers in the HFpEF model rats improved their
survival rate [20,21]. In addition, the improvement in survival rate
was dose-dependent (Fig. 1) [21].
In contrast to HFrEF, there have been only a few clinical trials to
investigate the effects of b-blockers on HFpEF. The subanalysis of the
SENIORS trial showed that the effects of nebivolol were similar
between HF patients with EF> and 35% [22]. The SWEDIC study did
not assess clinical outcomes but compared the changes in several
Doppler echocardiographic indices of the transmitral and pulmo-
nary venous ﬂow velocity patterns such as E/A ratio, deceleration
time of E wave, isovolumic relaxation time, and the ratio of systolic/
diastolic pulmonary venous ﬂow velocity between HFpEF patients
treated with and without carvedilol. The SWEDIC study concluded
that treatment with carvedilol resulted in a signiﬁcant improvement
in E/A ratio in patients with HF due to a LV relaxation abnormality
[23]. However, these Doppler echocardiographic indices have manyTable 1
Clinical trials to investigate the effects of pharmacological intervention except
b-blocker on clinical outcomes of heart failure with preserved ejection fraction.
Trial Drug Primary endpoint
DIG ancillary [50] Digitalis HF mortality or HF hospitalization
PEP-CHF [14] ACEI All-cause death or HF hospitalization
CHARM-Preserved [15] ARB CV death or HF hospitalization
I-Preserve [16] ARB All-cause death or CV hospitalization
TOP-CAT [17] MRB CV death, aborted cardiac arrest, or HF
hospitalization
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; CV, cardiovascular; HF, heart failure; MRB, mineralocorticoid receptor
blocker.limitations for the assessment of LV diastolic function in subjects
with preserved EF [24,25], and thus, it is difﬁcult to make conclusive
remarks based on the results of the SWEDIC study.
Because of a lack of evidence about the effects of b-blockers on
HFpEF, the J-DHF study was organized in Japan [26]. The number of
the enrolled subjects was 245, and they were randomly divided
into two groups treated with and without carvedilol. Mean age was
72 years, and 58% of the patients were men. The median follow-up
period was 3.2 years, and there was no signiﬁcant difference in the
incidence of the primary endpoint (cardiovascular death or
unplanned hospitalization for HF) and another composite endpoint
(cardiovascular death or unplanned hospitalization for any
cardiovascular causes) between the two groups. In Japan, the
maximal dose of carvedilol allowed for the treatment of HFrEF in
the insurance system is 20 mg/day, and the same dose was adopted
as the target dose in J-DHF study. However, the median and mean
prescribed doses were 7.5 and 8.5 mg/day, respectively. The
underdose in the prescription of b-blockers for HFrEF patients is
often observed in Japan as well as other western countries
[27,28]. The J-DHF study was a prospective, randomized, open,
blinded-endpoint design, and thus, the tendency to prescribe the
low dose of b-blocker in the treatment of HFrEF might inﬂuence
the actually prescribed dose of carvedilol in the subjects of the
J-DHF study. Although not prespeciﬁed, the effects of the dose were
assessed, and we found that the prescription of carvedilol more
than 7.5 mg/day was associated with a signiﬁcant reduction in the
incidence of cardiovascular death or unplanned hospitalization for
any cardiovascular causes (Fig. 2). Therefore, the results of the
J-DHF study suggest that the standard dose prescription of
carvedilol is effective in HFpEF.
Currently, there are no other prospective and randomized trials
to investigate the effects of b-blockers on HFpEF, but the results of
observational studies have been published. Several studies [29–36]
as well as the meta-analysis of 12 previous studies [37] have
reported that b-blockers provide beneﬁcial effects on HFpEF
(Fig. 3). In particular, the number of the subjects in three studies
[30,32,36] was more than 10,000, and two studies [31,34]
indicated the importance of the dose of b-blocker as the J-DHF
study did. In contrast, some studies have concluded that b-blockers
are not effective in HFpEF [38–42]. Although the OPTIMIZE-HF
study [40] included 4153 patients, the number of the subjects in
the other studies was less than 500. None of the ﬁve studies paid
attention to the dose of b-blockers of the study subjects. If there is
Fig. 2. Kaplan–Meier curves showing the time to ﬁrst occurrence of the prespeciﬁed
outcome, cardiovascular death or unplanned hospitalization for any cardiovascular
causes. The carvedilol group was further divided into a group treated with
carvedilol >7.5 mg/day (n = 58, standard-dose group) and carvedilol 7.5 mg/day
(n = 62, low-dose group). Control group consists of heart failure with preserved
ejection fraction patients treated without b-blocker. CI, conﬁdence interval; HR,
hazard ratio.
Reproduced with permission from Yamamoto et al. [26].
Fig. 3. Survival curves for all-cause mortality in HF patients treated with or without carv
were adjusted for age, sex, chronic obstructive pulmonary disease, and LV ejection fract
reduced ejection fraction.
Reproduced with permission from Yanagihara et al. [35].
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previous studies [26,31,34] have suggested, the conclusion about
the effects of b-blockers on HFpEF in the observational studies is
inﬂuenced by the patient characteristics. If the prevalence of
patients treated with low dose, i.e. less than a half of the target
dose, of b-blocker is high in the group treated with b-blockers, the
incidence of clinical outcomes may not be different between
groups treated with and without b-blockers. The HFrEF patients
enrolled in the OPTIMIZE-HF study were treated with b-blockers at
low doses [28]. It is plausible to speculate that the HFpEF patients
of the OPTIMIZE-HF study were also treated with low doses of
b-blockers, and that the absence of beneﬁcial effects of b-blocker
on HFpEF in the OPTIMIZE-HF study was at least partly explained
by the underdose of b-blockers. Recently, further analysis of
OPTIMIZE-HF concluded that the dose of b-blocker does not affect
the clinical outcome in HFpEF patients [43]; however, the median
follow-up was only 2.2 years. Shah et al. demonstrated that
beneﬁts of b-blockers emerged at follow-up for 3 years but not for
1 year in patients with HFpEF [32]. Thus, dose and duration of
b-blocker therapy may be key determinants of the effects of
b-blockers on clinical events in HFpEF patients.
Heart rate in HFpEF
b-Blockers have a negative chronotropic action and are
expected to reduce heart rate. An increase in heart rate in patients
with HF is associated with the exacerbation of mortality, and thus,
there has been a long controversy about whether the reduction inedilol at discharge. (A) Overall (HFrEF and HFpEF), (B) HFrEF, and (C) HFpEF, which
ion. HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with
Fig. 4. Comparison of LV pressure–volume loop between normal and HFpEF subjects. The increase in LV end-diastolic volume (dotted line) results in the greater elevation of
LV end-diastolic pressure in HFpEF because of the steeper end-diastolic pressure–volume curve. EDPVR, end-diastolic pressure–volume relation; HFpEF, heart failure with
preserved ejection fraction; LV, left ventricular.
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plausibly argued that the elevation of heart rate leads to the
shortening of diastolic ﬁlling period and the consequent elevation
of LV ﬁlling pressure. This is partly true; however, does the
reduction of heart rate always result in the reduction in LV ﬁlling
pressure? To keep cardiac output, the reduction in heart rate
should be compensated by the increase in stroke volume. In
patients with HFpEF, the slope of end-systolic pressure volume
relation (end-systolic elastance) is high [44], and their contractile
reserve is likely impaired. Therefore, the increase in end-diastolic
volume is required to increase stroke volume following the law of
Frank–Starling. As shown in Fig. 4, the slope of end-diastolic
pressure–volume curve is steeper in HFpEF patients as compared
to normal subjects. The increase in LV end-diastolic volume
results in a greater elevation of LV end-diastolic pressure in
HFpEF patients than in normal subjects, indicating that the
reduction in heart rate does not necessarily lead to a decrease in
LV ﬁlling pressure. Appropriate heart rate varies in HFpEF
patients, and it is likely wrong to uniformly reduce heart rate
in HFpEF patients.Fig. 5. Representative immunohistochemical staining for 4-hydroxy-2-nonenal (HNE) in 
preserved ejection fraction (HFpEF) model rat of an untreated group (Untreated), a HFpEF
and a group treated with high dose of bisoprolol (250 mg/kg/day, High dose). The ad
administered dose.
Reproduced with permission from Nishio et al. [21].What is expected from b-blockers in HFpEF?
The beneﬁcial effects of b-blockers in HFrEF are established.
Although the administration of b-blockers in HFrEF results in the
reduction of heart rate, the subanalysis of CIBIS II trial revealed that
the beneﬁcial effects of bisoprolol cannot be fully explained by the
reduction in heart rate [45]. In fact, bucindolol signiﬁcantly
decreased heart rate in HFrEF patients, but did not improve clinical
outcomes [46]. The mechanisms of the beneﬁts of b-blockers in
HFrEF are still to be established, and it is also unclear what we can
expect from b-blockers in the treatment of HFpEF even if the
results of the previous studies that showed beneﬁcial effects of
b-blockers, especially at high dose, on HFpEF are accepted.
Our experimental study [21] showed that the bisoprolol-
induced dose-dependent improvement in survival rate of HFpEF
model rats was provided through the combination of the
prevention of LV hypertrophy and ﬁbrosis, and that these effects
were associated with the attenuation of LV stiffening in spite of the
exacerbation of LV relaxation abnormality. The subanalysis of the
J-DHF study [47] showed that the beneﬁcial effects of a standardthe left ventricular tissue of a normotensive control rat (Control), a heart failure with
 model rat of a group treated with low dose of bisoprolol (12.5 mg/kg/day, Low dose)
ministration of bisoprolol attenuated the HNE staining with the increase in the
K. Yamamoto / Journal of Cardiology 66 (2015) 189–194 193dose (a half of the target dose) of carvedilol were greater in
patients with larger left atrial dimension, which suggests that
carvedilol provides greater beneﬁts in patients with advanced
diastolic dysfunction.
The underlying mechanisms of such beneﬁts remain to be
clariﬁed. Anti-inﬂammatory and anti-oxidative effects are likely
common in b-blockers which are recommended for the treatment
of HFrEF [48,49], and bisoprolol provided anti-inﬂammatory and
anti-oxidative effects in association with the improvement in
survival rate in the HFpEF model rat (Fig. 5) [21]. Thus, the
suppression of inﬂammatory changes and oxidative stress may be
one of the mechanisms of beneﬁcial effects of b-blockers on
cardiac structure and function.
Conclusions
Currently, there is no established therapeutic intervention to
improve the prognosis of HFpEF. One of the candidates is b-blocker
treatment. The previous observational studies provided inconsistent
conclusions about their effects on HFpEF; however, the absence of
the beneﬁts of b-blockers was drawn without taking into account
the dose of b-blockers and/or the duration of the prescription. The
long-term administration of standard doses of b-blockers may
provide beneﬁcial effects on HFpEF, and future studies are awaited
to make a conclusive remark about the effects of b-blockers in
HFpEF. However, a ‘‘one size ﬁts all approach’’ as in previous clinical
trials is likely inappropriate to ﬁnd out an effective therapeutic
strategy in HFpEF, because the pathophysiology of HFpEF is
heterogeneous. Future clinical studies may be required to target a
part of HFpEF with some speciﬁc characteristics.
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